B3 at-risk lesion of uncertain malignant potential, the highest-risk in its group. Vacuum-assisted excision first, surgical excision near-systematic per the French SENORIF 2025-2026 reference.
Author and medical review: Dr Jérémie Zeitoun, cancer surgeon (breast & gynaecology) — RPPS 10101463296 — trained at Institut Gustave Roussy, Institut Curie and Centre François Baclesse. See full background →
Last updated: · Sources: SENORIF 2025-2026, SFSPM, CNGOF, Rubio EJSO 2024, NICE. References at the bottom of the page.
Atypical ductal hyperplasia — abbreviated ADH — is an atypical epithelial proliferation that develops inside the galactophoric ducts of the breast, without meeting the diagnostic criteria of ductal carcinoma in situ. It is an at-risk lesion classified B3 (uncertain malignant potential), the highest-risk of its group.
Why the highest-risk B3 lesion: ADH stands out from other B3 lesions (papilloma, classic lobular carcinoma in situ, radial scar, atypical lobular hyperplasia) through a double risk — a high rate of cancer already present but undetected on biopsy (10 to 25% depending on the sampling technique), and an increased risk of subsequent breast cancer (multiplied by 4 to 5 compared to the general population), bilaterally.
ADH does not strictly degenerate into cancer. It reflects a particular fragility of breast tissue, which may evolve into cancer at a distance, independently of the ADH itself. This dual dimension — cancer possibly already present, and bilateral risk marker — justifies the specific management and the prolonged follow-up.
The histological distinction between ADH and low-grade ductal carcinoma in situ is sometimes subtle. The difference lies in the extent of the atypia: when it entirely occupies one duct or several adjacent ducts, the diagnosis is ductal carcinoma in situ; when it remains focal, it is ADH. Interobserver concordance among pathologists is lower for these borderline lesions than for cancers. Dr Zeitoun may request expert pathology review in case of doubt, and the final decision is always taken at MDT (multidisciplinary meeting) after full analysis of the surgical specimen.
There is no single identified cause for atypical ductal hyperplasia. It reflects a particular sensitivity of breast tissue to proliferative evolution, under the combined influence of several factors.
ADH is typically diagnosed between 40 and 60, as part of organised screening or follow-up mammography. More rarely before 40, in the context of family history or genetic risk.
Family history of breast cancer, dense breasts, prolonged hormonal exposure (long-term menopausal hormone therapy). Genetic predisposition (BRCA) should be investigated in case of family history.
To note: the presence of ADH is in itself a risk marker. It multiplies by 4 to 5 the risk of developing breast cancer in the following years, bilaterally. This justifies prolonged follow-up over at least 10 years, by annual bilateral mammography and ultrasound.
Source: SENORIF 2025-2026 · SFSPM
Atypical ductal hyperplasia is a lesion without clinical expression. It causes no pain, no palpable nodule, no nipple discharge, no skin change. This is precisely why mammographic screening is so important — it allows the detection of lesions that would never be seen clinically.
Main radiological sign: a focus of microcalcifications on mammography, most often classified ACR 4 (suspicious).
More rarely, ADH is found incidentally on a biopsy performed for another abnormality (nodule, architectural distortion).
No discharge, no palpable nodule, no nipple retraction. ADH is a silent lesion, detected radiologically.
The importance of screening: since ADH is silent, only regular mammographic screening allows its detection. French recommendations provide for mammography every 2 years between 50 and 74 years as part of organised screening, and earlier in case of family history or at-risk context.
Source: SFSPM · HAS · INCa
Diagnosis relies on a structured approach: screening mammography detecting the microcalcifications, imaging workup, then stereotactic vacuum-assisted excision. The particular feature of ADH — compared with papilloma — is that diagnosis requires a vacuum-assisted excision upfront, not a simple core biopsy.
Detection of a focus of microcalcifications classified ACR 4 (suspicious). Most often as part of organised screening between 50 and 74 years, or individualised surveillance.
Bilateral breast ultrasound. Breast MRI case-by-case (dense breasts, extension workup of microcalcifications, strong family history, BRCA mutation).
Stereotactic vacuum-assisted excision (Mammotome) — reference technique for microcalcifications. Systematic placement of a metal clip (Twirl).
Why vacuum-assisted excision rather than core biopsy: for a focus of ACR 4 microcalcifications, a simple core biopsy does not sample a sufficient tissue volume — it exposes to an underestimation risk (undetected underlying cancer) of around 15 to 25%. Vacuum-assisted excision, by contrast, samples a much larger volume, reducing underestimation to 10 to 15%. This is why vacuum-assisted excision is the reference technique for suspicious microcalcifications, not core biopsy.
Source: SENORIF 2025-2026 · HAS · SFSPM
Unlike papilloma, where three therapeutic pathways are possible, ADH almost always leads to surgical excision. This is the reference strategy, validated by the SENORIF 2025-2026 reference and the European guidelines (Rubio EJSO 2024). Two reasons: the high rate of underestimation (cancer found on the specimen) and the nature of ADH itself, considered the highest-risk B3 lesion.
Underestimation rate: series report around 15 to 25% of associated cancers found at final excision when diagnosis rests on core biopsy, and 10 to 15% when it rests on vacuum-assisted excision — a rate still too high to be ignored. The surgical decision, validated at MDT, protects the patient against the risk of leaving an unrecognised cancer in place.
Unlike papilloma, where close radiological surveillance may be offered under specific conditions, ADH does not benefit from a surveillance-only option. The risk of leaving an occult cancer in place is judged too important. Similarly, vacuum-assisted excision alone, without complementary surgery, is not considered sufficient: it does not guarantee complete resection of the at-risk area and leaves diagnostic uncertainty at the margins.
During the stereotactic vacuum-assisted excision, the radiologist deposits a small metal clip (e.g. Twirl) at the exact location of the sampled microcalcifications. The clip has a dual role: to mark the target — since the microcalcifications may have entirely disappeared after the vacuum-assisted excision — and to serve as a landmark for the subsequent surgery. The clip is biologically inert, does not interfere with MRI or mammography, and can stay in place indefinitely without issue.
ADH is almost always a non-palpable lesion. Before surgery, a pre-operative localisation is essential to guide the surgeon. This localisation is placed at the metal clip deposited at the vacuum-assisted excision. Two techniques are available — the choice is made with the patient and the radiologist according to logistics and preferences.
Thin metal wire with one end anchored at the biopsy clip and the other end exiting the skin. Placed under stereotactic or ultrasound guidance, the day before or the morning of surgery. Historical technique, still widely used — reliable and inexpensive.
Small magnetic seed (Magseed, Localizer or Sirius) placed at the metal clip. Detected intraoperatively by a dedicated probe. Can be placed several weeks before surgery, simplifying logistics — no need to arrive fasting with a wire exiting the skin.
Surgical objective: remove en-bloc the localisation marker (hookwire or magnetic seed), the metal clip placed at the vacuum-assisted excision and the surrounding residual microcalcifications. A specimen radiograph is performed at the end of the procedure to confirm that both markers (or the hookwire and the metal clip) have been removed and that any residual microcalcifications have been taken with the specimen. The procedure is performed in theatre as day surgery, usually under general anaesthesia. Systematic histopathology.
Further reading: pre-operative localisation deserves its own page — technique, workflow, practical differences between hookwire and magnetic seed (Magseed, Localizer, Sirius), specimen radiography. Read the full page on pre-operative localisation →
Source: SENORIF 2025-2026 · Rubio EJSO 2024 · Elfgen Virchow Archiv 2023
Recovery after ADH excision is usually straightforward. What distinguishes ADH, beyond the immediate post-operative course, is a prolonged follow-up over at least 10 years, given the increased risk of subsequent breast cancer in the following years.
Moderate during the first 48 hours, well relieved by paracetamol.
3 to 7 days for a sedentary job. 10 to 15 days for a physical job.
Walking from the first days. Light sport at 2-3 weeks. Overhead activities deferred 3-4 weeks.
Report available in 2 to 3 weeks. Dedicated follow-up consultation to discuss it and organise the prolonged follow-up.
Key principle for ADH: an ADH is never re-excised, even in case of involved margins or residual atypia on the specimen (SENORIF 2025-2026). Only the discovery of an associated cancer changes management.
Dr Zeitoun does not offer preventive hormone therapy (tamoxifen, raloxifene) after ADH. Close prolonged surveillance remains the reference strategy.
Given the increased risk of subsequent breast cancer — including contralaterally — follow-up is intensive and prolonged. It is adapted to each patient's profile.
Bilateral mammography + breast ultrasound. Breast MRI if the initial diagnosis was made or completed by MRI.
Bilateral mammography + ultrasound annually for at least 10 years, ± MRI according to associated factors (dense breasts, family history, genetic context).
Why this prolonged follow-up: the risk of subsequent breast cancer — particularly in situ — is increased in the 10 to 15 years following an ADH diagnosis, bilaterally. Intensive surveillance allows early diagnosis of any cancers, most often at a curable stage. In this perspective, screening is preferred to chemoprevention — which exposes to significant side effects (thromboses, hot flushes, increased endometrial cancer risk under tamoxifen).
Source: SENORIF 2025-2026 · SFSPM
ADH excision is a very safe procedure, with a low complication rate. Dr Zeitoun details each risk during the pre-operative consultation — this information is part of shared decision-making and is systematic before any surgery.
Most important situation to anticipate: 10 to 15% of ADHs reveal an associated cancer (in situ or micro-invasive) on specimen analysis — 15 to 25% if the initial biopsy was a core biopsy. Management is then adapted at MDT: oncological re-excision with clear margins, ± sentinel lymph node biopsy depending on cancer type.
Risk of developing breast cancer in subsequent years is multiplied by 4 to 5 compared to the general population, bilaterally. This risk is what justifies the intensive 10-year follow-up — and what allows, if a cancer appears, early diagnosis at a curable stage.
Most frequent immediate post-operative complication. Usually moderate, resolves spontaneously within a few days. A large haematoma rarely requires surgical revision.
Very low risk (< 1%) thanks to strict theatre asepsis. Warning signs (redness, discharge, fever) warrant prompt consultation.
Keloid or hypertrophic scar possible depending on skin type. Topography adapted to the microcalcification location. Scar massage from 4 weeks optimises the result.
ADH excision does not compromise future breastfeeding in the majority of cases — the other galactophoric ducts of the breast function normally.
Source: SENORIF 2025-2026 · SFSPM · CNGOF
Paris 8th clinic · Clinique Hartmann Neuilly · Sector 2 non-OPTAM
The most frequent questions in consultation. Answers based on the SENORIF 2025-2026 reference, SFSPM and CNGOF recommendations, and everyday clinical practice.
No, ADH is not a cancer. It is a B3 at-risk lesion — it does not strictly degenerate into cancer, but it is associated with an occult cancer in 10 to 25% of cases (depending on whether diagnosis rests on core biopsy or vacuum-assisted excision). It also marks an increased risk of subsequent breast cancer in the following years, including contralaterally. This dual dimension justifies the near-systematic surgical excision and the prolonged follow-up.
ADH is most often detected on screening mammography, as a focus of microcalcifications classified ACR 4 (suspicious). It has no clinical expression — no pain, no palpable nodule, no discharge. The diagnosis is then confirmed by stereotactic vacuum-assisted excision (Mammotome system), which samples a large tissue volume to optimise the diagnosis.
For a focus of ACR 4 microcalcifications, stereotactic vacuum-assisted excision (Mammotome) is the reference technique. It samples a much larger volume than a simple core biopsy, which reduces the risk of underestimation — series report 15 to 25% of underlying cancers when diagnosis rests on core biopsy, versus 10 to 15% on vacuum-assisted excision. A metal clip (Twirl) is systematically placed at the end of the procedure, as the microcalcifications may have entirely disappeared after sampling.
Yes, in the vast majority of cases. Unlike papilloma, where surveillance and vacuum-assisted excision alone may be discussed, ADH almost always leads to surgical excision. The high underestimation rate (10 to 25% of cancers found on the specimen) and the very nature of ADH — the highest-risk B3 lesion — justify this strategy. The SENORIF 2025-2026 reference and the European guidelines (Rubio EJSO 2024) position surgery as the reference strategy.
ADH is almost always a non-palpable lesion. A metal clip (e.g. Twirl) was deposited during the initial vacuum-assisted excision. Before surgery, a pre-operative localisation is placed at this clip, either by wire localisation (hookwire) — thin wire exiting the skin, placed the day before or the morning of surgery — or by magnetic seed (Magseed, Localizer or Sirius), which can be placed several weeks in advance. Objective: remove en-bloc the hookwire or magnetic seed, the biopsy metal clip and the residual microcalcifications. A specimen radiograph confirms complete resection.
No. For ADH, re-excision is never performed — even in case of non-in-sano excision (involved margins) or residual atypia on the specimen (SENORIF 2025-2026). Important rule: unlike cancer, where clear margins are mandatory, ADH benefits from a conservative strategy confirmed by the latest recommendations. Only the discovery of an associated cancer on histopathological analysis changes management — it is then adapted at MDT with standard oncological re-excision.
Follow-up is essential because ADH multiplies by 4 to 5 the risk of subsequent breast cancer, bilaterally. In Dr Zeitoun's practice: a first mammo-ultrasound control at 6 months post-operatively (± MRI if the initial diagnosis was made or completed by MRI), then annual surveillance for at least 10 years by bilateral mammography + ultrasound (± MRI depending on context). This prolonged surveillance allows early diagnosis of any subsequent cancers, most often in situ and at a curable stage.
No. Dr Zeitoun does not offer chemoprevention by tamoxifen or raloxifene after ADH. Although some anglophone publications suggest a reduction in risk under preventive hormone therapy, the side effects of these treatments (venous thromboses, hot flushes, increased endometrial cancer risk under tamoxifen) are not considered acceptable in this context, where close prolonged surveillance allows early diagnosis of any recurrence. The chosen strategy is therefore annual surveillance over 10 years, not medication.
Yes. ADH is considered a bilateral risk marker: it reflects a fragility of breast tissue that concerns both breasts. This is why prolonged surveillance is bilateral, even if surgery concerned only one side. This increased risk particularly involves in situ cancers, which fortunately have an excellent prognosis when detected early.
Dr Zeitoun practises in sector 2 non-OPTAM: additional fees apply. ADH excision is covered by French Assurance Maladie at the contractual rate. A personalised quote is systematically provided after the consultation. Out-of-pocket expenses depend on your complementary health insurance.
This page relies on the French SENORIF 2025-2026 reference, recommendations from French and international medical societies, and on recent medical literature indexed in PubMed.
Last reviewed: 22 April 2026 · Next scheduled update: October 2026.
Paris 8th clinic or Clinique Hartmann Neuilly. Second opinion possible on records.